Transcriptional Profile of Native CD271+ Multipotential Stromal Cells: Evidence for Multiple Fates, with Prominent Osteogenic and Wnt Pathway Signaling Activity
Overview
Authors
Affiliations
Objective: Controversy surrounds the identity and functionality of rare bone marrow-derived multipotential stromal cells (BM-MSCs), including their differentiation capabilities, their relationship to pericytes and hematopoiesis-supporting stromal cells, and the relevance of their culture-expanded progeny in studies of skeletal biology and development of cell-based therapies. The aim of this study was to clarify the nature of candidate BM-MSCs by profiling transcripts that reflect different aspects of their putative functions in vivo.
Methods: Rare, sorted BM-derived CD45(-/low) CD271(bright) (CD271) cells were analyzed using 96-gene expression arrays focused on transcripts relevant to mesenchymal-lineage differentiation (toward bone, cartilage, fat, or muscle), hematopoietic and stromal support, and molecules critical to skeletal homeostasis. These cells were compared to matched CD45+ CD271- hematopoietic-lineage cells, culture-expanded MSCs, and skin fibroblasts. When feasible, transcription was validated using flow cytometry.
Results: CD271 cells had a transcriptional profile consistent with the multiple fates of in vivo MSCs, evident from the observed simultaneous expression of osteogenic, adipogenic, pericytic, and hematopoiesis-supporting genes (e.g., SP7 [osterix], FABP4 [fatty acid binding protein 4], ANGPT1 [angiopoietin 1], and CXCL12 [stromal cell-derived factor 1], respectively). Compared to culture-expanded MSCs and fibroblasts, CD271 cells exhibited greater transcriptional activity, particularly with respect to Wnt-related genes (>1,000-fold increased expression of FRZB [secreted frizzled-related protein 3] and WIF1 [Wnt inhibitory factor 1]). A number of transcripts were identified as novel markers of MSCs.
Conclusion: The native, BM-derived in vivo MSC population is endowed with a gene signature that is compatible with multiple functions, reflecting the topographic bone niche of these cells, and their signature is significantly different from that of culture-expanded MSCs. This indicates that studies of the biologic functions of MSCs in musculoskeletal diseases, including osteoporosis and osteoarthritis, should focus on in vivo MSCs, rather than their culture-adapted progeny.
Hisamatsu D, Ikeba A, Yamato T, Mabuchi Y, Watanabe M, Akazawa C Inflamm Regen. 2024; 44(1):37.
PMID: 39152520 PMC: 11328379. DOI: 10.1186/s41232-024-00350-5.
Hughes A, Kuek V, Oommen J, Kotecha R, Cheung L Sci Rep. 2024; 14(1):12396.
PMID: 38811646 PMC: 11137146. DOI: 10.1038/s41598-024-63009-8.
Plecko M, Kovacic N, Grcevic D, Sucur A, Vukasovic Barisic A, Duvancic T Int J Mol Sci. 2024; 25(10).
PMID: 38791213 PMC: 11121609. DOI: 10.3390/ijms25105173.
Hussein N, Meade J, Pandit H, Jones E, El-Gendy R Int J Mol Sci. 2024; 25(5).
PMID: 38474098 PMC: 10931945. DOI: 10.3390/ijms25052851.
Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities.
Vukotic M, Kapor S, Simon F, Cokic V, Santibanez J Heliyon. 2024; 10(3):e25081.
PMID: 38314300 PMC: 10837636. DOI: 10.1016/j.heliyon.2024.e25081.